Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Quentin30on Nov 27, 2023 4:49pm
151 Views
Post# 35755168

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:My, my.....Ithno and Ionc working overtime to trash Oncy....

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:My, my.....Ithno and Ionc working overtime to trash Oncy....actually Azzak, the science as yet is still 'UNPROVEN'. It will only be indefatigable (I prefer the term unassailable) when they have trial results that are statistically significant.

ONCY had a chance to start said mBC Phase III 5 years ago, but chose not to... It has wasted so much time, and all the while MC tells us he has been doing so to ensure shareholder value.

Hmmm, well, lets see where the chips fall by year end.. There are four definite inflection points for CRPR until March 2024.

1) FDA approval for Sickle Cell
2 EMA approval for same
3) SFDA approval for same
4) FDA approval for Beta Thalassemia

and analyst targets on ONCY have been reduced to $5... so what is the upside here for the associated risk... it's pitiful

Oh yes, someone, might make an offer of partnership and/or buyout, because Matt reiterated, as he has done for 7 years, that they are in talks... LOL... Let's be honest this stock is a complete gamble. Past performance is very telling.
<< Previous
Bullboard Posts
Next >>